Early-stage drug development typically comes with a heaping side of financial risk. As a result, promising academic research discoveries can languish in the uncertain R&D stages because there is no commercial funding to prove their market potential. Increasingly, nonprofits are stepping in to fill this gap, backing new ideas and bringing them to a point where pharma companies are willing to invest and carry them past the regulatory finish line.
